Comparative Pharmacology
Head-to-head clinical analysis: METAPROTERENOL SULFATE versus PROVENTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAPROTERENOL SULFATE versus PROVENTIL.
METAPROTERENOL SULFATE vs PROVENTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-2 adrenergic receptor agonist that activates adenylate cyclase, increasing intracellular cyclic AMP leading to bronchodilation and inhibition of mast cell mediator release.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP
2.5 mg (0.25 mL of 1% solution) by nebulization every 6-8 hours. For oral, 20 mg every 6-8 hours.
Inhalation: 2 inhalations (90 mcg each) every 4-6 hours as needed; oral: 2-4 mg three to four times daily; extended-release: 4-8 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 2-6 hours. Clinical context: Shorter half-life requires frequent dosing; prolongation in renal impairment.
Terminal elimination half-life: 3.8–6 hours (inhalation), 3.7–7.1 hours (oral); clinical context: supports dosing every 4–6 hours as needed.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites.
Renal: ~90% (mostly as sulfate conjugates after oral administration, unchanged drug after inhalation); biliary/fecal: <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist